



## Clinical trial results:

### A Single Arm Multi-Center Study Investigating the at Home Administration of Trastuzumab Subcutaneous Vial for the Treatment of Patients With HER2-Positive Early Breast Cancer

#### Summary

EudraCT number	2013-000123-13
Trial protocol	BE
Global end of trial date	19 July 2017

#### Results information

Result version number	v2 (current)
This version publication date	03 August 2018
First version publication date	03 February 2017
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	ML28794
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01926886
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
Scientific contact	Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 May 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	19 July 2017
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

This was a global prospective, non-randomized, open label phase IIIb study to evaluate the overall safety and tolerability of subcutaneous (SC) trastuzumab with assisted administration using a conventional syringe and needle (vial formulation, hereafter referred to as trastuzumab SC vial) when administered at home for the treatment of participants with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (eBC).

Protection of trial subjects:

The study was conducted in accordance with the principles of the "Declaration of Helsinki" and Good Clinical Practice (GCP) standards and according to the all local laws and regulations concerning clinical study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 November 2013
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	2 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 51
Country: Number of subjects enrolled	Israel: 51
Worldwide total number of subjects	102
EEA total number of subjects	51

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	82
From 65 to 84 years	20
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Participants with HER2+ eBC who completed the first 6 cycles of trastuzumab intravenous (IV) as part of the (neo) adjuvant treatment received 12 cycles of trastuzumab to complete a total of 18 cycles of trastuzumab were enrolled.

### Period 1

Period 1 title	Trastuzumab (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Trastuzumab
-----------	-------------

Arm description:

Participants received trastuzumab IV infusion at initial loading dose of 8 milligrams per kilogram (mg/kg) body weight (BW) for three-weekly (q3w) regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (Cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).

Arm type	Experimental
Investigational medicinal product name	Trastuzumab
Investigational medicinal product code	
Other name	Herceptin
Pharmaceutical forms	Injection, Powder for concentrate for solution for infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.

Number of subjects in period 1	Trastuzumab
Started	102
Received at least 1 dose of study drug	101
Completed	70
Not completed	32
Consent withdrawn by subject	15
Recurrence of disease	1
Failure to return	3
Adverse event/intercurrent illness	4
Death	1
Administrative/other	1
Disease progression/recurrence	4

Progression of disease	2
Did not cooperate	1

## Baseline characteristics

### Reporting groups

Reporting group title	Trastuzumab
-----------------------	-------------

Reporting group description:

Participants received trastuzumab IV infusion at initial loading dose of 8 milligrams per kilogram (mg/kg) body weight (BW) for three-weekly (q3w) regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (Cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).

Reporting group values	Trastuzumab	Total	
Number of subjects	102	102	
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	54.38 ± 12.28	-	
Gender categorical Units: Subjects			
Female	101	101	
Male	1	1	
Race (NIH/OMB) Units: Subjects			
White	98	98	
Black	1	1	
Asian	2	2	
Missing	1	1	

## End points

### End points reporting groups

Reporting group title	Trastuzumab
Reporting group description:	
Participants received trastuzumab IV infusion at initial loading dose of 8 milligrams per kilogram (mg/kg) body weight (BW) for three-weekly (q3w) regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (Cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).	

### Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point title	Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) <sup>[1]</sup>
End point description:	
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non-serious AEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An emergent AE was defined as occurring within 35 days after last treatment administration. Safety population included all enrolled participants who received at least one dose of study medication.	
End point type	Primary
End point timeframe:	
Up to 45 months	
Notes:	
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: Descriptive statistics only	

End point values	Trastuzumab			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Percentage of participants				
number (not applicable)				
Emergent AE	90.1			
Emergent SAE	7.9			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 1 (PSQ1): In-Hospital

End point title	Number of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 1 (PSQ1): In-Hospital
End point description:	
PSQ1 is a quality of care questionnaire containing 14 questions each of Sections A & B (total 28	

questions) categorized on opinion of participants about clinicians, other staff & other questions. Responses to questions with section A were categorized to "not at all", "to a small extent", "to a moderate extent", "to a large extent", "to a very large extent", "Not applicable" & "missing". Responses to questions with section B categorized to "Not important", "a little important", "important", "very important", "of utmost importance", "not applicable" & "missing". Responses to question 11 with section A were categorized to "Yes, but not long", "yes, quite long", "yes, much long" & "missing". Participant experience with treatment provided during in-hospital part of study was evaluated with PSQ1 completed by participant prior to first dose of trastuzumab SC at home. Intent-to-Treat (ITT) population included all enrolled participants. Number of participants analyzed (N): participants evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (0 hour) to first trastuzumab SC administration at Cycle 13 (Cycle length=21 days)

End point values	Trastuzumab			
Subject group type	Reporting group			
Number of subjects analysed	86			
Units: Participants				
number (not applicable)				
1a: Clinician Communication-Not at all	0			
1a: Clinician Communication-To a small extent	4			
1a: Clinician Communication-To a moderate extent	8			
1a: Clinician Communication-To a large extent	22			
1a: Clinician Communication-To a very large extent	49			
1a: Clinician Communication-Not applicable	0			
1a: Clinician Communication-Missing	3			
1b: Importance-Not important	1			
1b: Importance-A little important	3			
1b: Importance-Important	19			
1b: Importance-Very important	40			
1b: Importance-Of utmost importance	21			
1b: Importance-Not applicable	0			
1b: Importance-Missing	2			
2a: Confidence in clinicians-Not at all	0			
2a: Confidence in clinicians-To a small extent	0			
2a: Confidence in clinicians-To a moderate extent	5			
2a: Confidence in clinicians-To a large extent	23			
2a: Confidence in clinicians-To a very large extent	56			
2a: Confidence in clinicians-Not Applicable	0			
2a: Confidence in clinicians-Missing	2			
2b: Importance-Not important	0			
2b: Importance-A little important	1			
2b: Importance-Important	13			
2b: Importance-Very important	44			
2b: Importance-Of utmost importance	25			



2b:Importance-Not applicable	0			
2b:Importance-Missing	3			
3a:Clinicians cared about you-Not at all	2			
3a:Clinicians cared about you-To a small extent	1			
3a:Clinicians cared about you-To a moderate extent	6			
3a:Clinicians cared about you-To a large extent	24			
3a:Clinicians cared about you-To very large extent	51			
3a:Clinicians cared about you-Not applicable	0			
3a:Clinicians cared about you-Missing	2			
3b:Importance-Not important	0			
3b:Importance-A little important	2			
3b:Importance-Important	16			
3b:Importance-Very important	47			
3b:Importance-Of utmost importance	18			
3b:Importance-Not applicable	0			
3b:Importance-Missing	3			
4a:Clinicians interested-Not at all	0			
4a:Clinicians interested-To a small extent)	2			
4a:Clinicians interested-To a moderate extent	12			
4a:Clinicians interested-To a large extent	29			
4a:Clinicians interested-To a very large extent	40			
4a:Clinicians interested-Not applicable	1			
4a:Clinicians interested-Missing	2			
4b:Importance-Not important	0			
4b:Importance-A little important	2			
4b:Importance-Important	15			
4b:Importance-Very important	51			
4b:Importance-Of utmost importance	15			
4b:Importance-Not applicable	0			
4b:Importance-Missing	3			
5a:Time with clinicians-Not at all	1			
5a:Time with clinicians-To small extent	4			
5a:Time with clinicians-To a moderate extent	12			
5a:Time with clinicians-To a large extent	26			
5a:Time with clinician-To a very large extent	39			
5a:Time with clinicians-Not applicable	1			
5a:Time with clinicians-Missing	3			
5b:Importance-Not important	0			
5b:Importance-A little important	2			
5b:Importance-Important	21			
5b:Importance-Very important	45			
5b:Importance-Of utmost importance	14			
5b:Importance-Not applicable	0			
5b:Importance-Missing	4			

6a:Nurses communication-Not at all	0			
6a:Nurses communication-To a small extent	1			
6a:Nurses communication-To a moderate extent	4			
6a:Nurses communication-To a large extent	19			
6a:Nurses communication-To a very large extent	60			
6a:Nurses communication-Not Applicable	0			
6a:Nurses communication-Missing	2			
6b:Importance-Not important	1			
6b:Importance-A little important	4			
6b:Importance-Important	18			
6b:Importance-Very important	44			
6b:Importance-Of utmost importance	16			
6b:Importance-Not applicable	0			
6b:Importance-Missing	3			
7a:Confidence in nurses-Not at all	0			
7a:Confidence in nurses-To a small extent	0			
7a:Confidence in nurses-To a moderate extent	4			
7a:Confidence in nurses-To a large extent	19			
7a:Confidence in nurses-To a very large extent	61			
7a:Confidence in nurses-Not Applicable	0			
7a:Confidence in nurses-Missing	2			
7b:Importance-Not important	0			
7b:Importance-A little important	1			
7b:Importance-Important	17			
7b:Importance-Very important	46			
7b:Importance-Of utmost importance	19			
7b:Importance-Not applicable	0			
7b:Importance-Missing	3			
8a:Nurses cared about you-Not at all	1			
8a:Nurses cared about you-To a small extent	2			
8a:Nurses cared about you-To a moderate extent	4			
8a:Nurses cared about you-To a large extent	25			
8a:Nurses cared about you-To a very large extent	52			
8a:Nurses cared about you-Not Applicable	0			
8a:Nurses cared about you-Missing	2			
8b:Importance-Not important	0			
8b:Importance-A little important	3			
8b:Importance-Important	22			
8b:Importance-Very important	41			
8b:Importance-Of utmost importance	17			
8b:Importance-Not applicable	0			
8b:Importance-Missing	3			

9a:Nurses interested-Not at all	0			
9a:Nurses interested-To a small extent	3			
9a:Nurses interested-To a moderate extent	3			
9a:Nurses interested-To a large extent	22			
9a:Nurses interested-To a very large extent	56			
9a:Nurses interested-Not Applicable	0			
9a:Nurses interested-Missing	2			
9b:Importance-Not important	0			
9b:Importance-A little important	5			
9b:Importance-Important	22			
9b:Importance-Very important	41			
9b:Importance-Of utmost importance	14			
9b:Importance-Not applicable	0			
9b:Importance-Missing	4			
10a:Time with nurses-Not at all	0			
10a:Time with nurses-To a small extent	4			
10a:Time with nurses-To a moderate extent	10			
10a:Time with nurses-To a large extent	20			
10a:Time with nurses-To a very large extent	49			
10a:Time with nurses-Not Applicable	1			
10a:Time with nurses-Missing	2			
10b:Importance-Not important	0			
10b:Importance-A little important	5			
10b:Importance-Important	21			
10b:Importance-Very important	40			
10b:Importance-Of utmost importance	15			
10b:Importance-Not applicable	0			
10b:Importance-Missing	5			
11a:Waited for hospital admission-No	24			
11a:Waited for hospital admission-Yes, but not long	34			
11a:Waited for hospital admission-Yes, quite long	20			
11a:Waited for hospital admission-Yes, much long	4			
11a:Waited for hospital admission-Missing	4			
11b:Importance-Not important	5			
11b:Importance-A little important	12			
11b:Importance-Important	28			
11b:Importance-Very important	24			
11b:Importance-Of utmost importance	12			
11b:Importance-Not applicable	0			
11b:Importance-Missing	5			
12a:Clinic equipment good order-Not at all	0			
12a:Clinic equipment good order-To a small extent	1			
12a:Clinic equipment good order-To moderate extent	3			
12a:Clinic equipment good order-To a large extent	34			

12a: Clinic equipment good order-To very large extent	46			
12a: Clinic equipment good order-Not applicable	0			
12a: Clinic equipment in good order-Missing	2			
12b: Importance-Not important	0			
12b: Importance-A little important	0			
12b: Importance-Important	22			
12b: Importance-Very important	41			
12b: Importance-Of utmost importance	20			
12b: Importance-Not applicable	0			
12b: Importance-Missing	3			
13a: Clinic otherwise good order-Not at all	0			
13a: Clinic otherwise good order-To a small extent	1			
13a: Clinic otherwise good order-To moderate extent	5			
13a: Clinic otherwise good order-To a large extent	32			
13a: Clinic otherwise good order-To very large extent	45			
13a: Clinic otherwise good order-Not Applicable	0			
13a: Clinic otherwise good order-Missing	3			
13b: Importance-Not important	0			
13b: Importance-A little important	2			
13b: Importance-Important	23			
13b: Importance-Very important	39			
13b: Importance-Of utmost importance	18			
13b: Importance-Not applicable	0			
13b: Importance-Missing	4			
14a: Satisfactory treatment-Not at all	0			
14a: Satisfactory treatment-To a small extent	0			
14a: Satisfactory treatment-To a moderate extent	1			
14a: Satisfactory treatment-To a large extent	18			
14a: Satisfactory treatment-To a very large extent	65			
14a: Satisfactory treatment-Not Applicable	0			
14a: Satisfactory treatment-Missing	2			
14b: Importance-Not important	0			
14b: Importance-A little important	3			
14b: Importance-Important	12			
14b: Importance-Very important	43			
14b: Importance-Of utmost importance	25			
14b: Importance-Not applicable	0			
14b: Importance-Missing	3			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 2 (PSQ2): At Home

End point title	Number of Participants With Modalities Assessed Using Patient Satisfaction Questionnaire 2 (PSQ2): At Home
-----------------	--

End point description:

PSQ2 is a quality of care questionnaire containing 13 questions each of Sections A and B, with a total of 26 questions categorized on the opinion of participants about the clinicians, opinion of participant about the other staff and other questions. Responses to questions with section A were categorized to "Not at all", "To a small extent", "to a moderate extent", "to a large extent", "to a very large extent", "Not applicable" and "missing". Responses to questions with section B were categorized to "Not important", "a little important", "important", "very important", "of utmost importance", "not applicable" and "missing". Participant experience with the treatment provided during the at-home part of the study was evaluated with the PSQ2 questionnaire completed by the participant prior to the fifth dose of trastuzumab SC at home. ITT population. Here, N=participants who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (0 hour) to fifth trastuzumab SC administration at Cycle 17 (Cycle length=21 days)

End point values	Trastuzumab			
Subject group type	Reporting group			
Number of subjects analysed	83			
Units: Participants				
number (not applicable)				
1a:Clinicians communication-Not at all	0			
1a:Clinicians communication-To a small extent	3			
1a:Clinicians communication-To a moderate extent	8			
1a:Clinicians communication-To a large extent	28			
1a:Clinicians communication-To a very large extent	34			
1a:Clinicians communication-Not Applicable	7			
1a:Clinicians communication-Missing	3			
1b:Importance-Not important	2			
1b:Importance-A little important	0			
1b:Importance-Important	20			
1b:Importance-Very important	37			
1b:Importance-Of utmost importance	16			
1b:Importance-Not applicable	0			
1b:Importance-Missing	8			
2a:Confidence in the clinicians-Not at all	0			
2a:Confidence in the clinicians-To a small extent	1			
2a:Confidence in the clinicians-To moderate extent	2			
2a:Confidence in the clinicians-To a large extent	20			

2a:Confidence in the clinician-To verylarge extent	51			
2a:Confidence in the clinicians-Not applicable	5			
2a:Confidence in the clinicians-Missing	4			
2b:Importance-Not important	0			
2b:Importance-A little important	0			
2b:Importance-Important	14			
2b:Importance-Very important	38			
2b:Importance-Of utmost importance	23			
2b:Importance-Not applicable	0			
2b:Importance-Missing	8			
3a:Clinicians cared about you-Not at all	2			
3a:Clinicians cared about you-To a small extent	1			
3a:Clinicians cared about you-To a moderate extent	6			
3a:Clinicians cared about you-To a large extent	22			
3a:Clinician cared about you-To very large extent	42			
3a:Clinicians cared about you-Not Applicable	6			
3a:Clinicians cared about you-Missing	4			
3b:Importance-Not important	0			
3b:Importance-A little important	1			
3b:Importance-Important	20			
3b:Importance-Very important	34			
3b:Importance-Of utmost importance	20			
3b:Importance-Not applicable	0			
3b:Importance-Missing	8			
4a:Clinicians interested-Not at all	0			
4a:Clinicians interested-To a small extent	1			
4a:Clinicians interested-To a moderate extent	9			
4a:Clinicians interested-To a large extent	27			
4a:Clinicians interested-To a very large extent	36			
4a:Clinicians interested-Not applicable	6			
4a:Clinicians interested-Missing	4			
4b:Importance-Not important	0			
4b:Importance-A little important	1			
4b:Importance-Important	19			
4b:Importance-Very important	34			
4b:Importance-Of utmost importance	21			
4b:Importance-Not applicable	0			
4b:Importance-Missing	8			
5a:Clinicians interaction-Not at all	1			
5a:Clinicians interaction-To a small extent	0			
5a:Clinicians interaction-To moderate extent	11			
5a:Clinicians interaction-To a large extent	31			

5a:Clinicians interaction-To very large extent	30			
5a:Clinicians interaction-Not Applicable	6			
5a:Clinicians interaction-Missing	4			
5b:Importance-Not important	0			
5b:Importance-A little important	0			
5b:Importance-Important	22			
5b:Importance-Very important	35			
5b:Importance-Of utmost importance	18			
5b:Importance-Not applicable	0			
5b:Importance-Missing	8			
6a:Nurses communication-Not at all	0			
6a:Nurses communication-To a small extent	1			
6a:Nurses communication-To a moderate extent	1			
6a:Nurses communication-To a large extent	17			
6a:Nurses communication-To a very large extent	62			
6a:Nurses communication-Not applicable	1			
6a:Nurses communication-Missing	1			
6b:Importance-Not important	0			
6b:Importance-A little important	0			
6b:Importance-Important	22			
6b:Importance-Very important	39			
6b:Importance-Of utmost importance	21			
6b:Importance-Not applicable	0			
6b:Importance-Missing	1			
7a:Confidence in the nurses-Not at all	0			
7a:Confidence in the nurses-To a small extent	0			
7a:Confidence in the nurses-To a moderate extent	1			
7a:Confidence in the nurses-To a large extent	23			
7a:Confidence in the nurses-To a very large extent	58			
7a:Confidence in the nurses-Not applicable	0			
7a:Confidence in the nurses-Missing	1			
7b:Importance-Not important	0			
7b:Importance-A little important	1			
7b:Importance-Important	17			
7b:Importance-Very important	41			
7b:Importance-Of utmost importance	23			
7b:Importance-Not applicable	0			
7b:Importance-Missing	1			
8a:Nurses cared about you-Not at all	0			
8a:Nurses cared about you-To a small extent	0			
8a:Nurses cared about you-To a moderate extent	2			
8a:Nurses cared about you-To a large extent	23			

8a:Nurses cared about you-To a very large extent	57			
8a:Nurses cared about you-Not applicable	0			
8a:Nurses cared about you-Missing	1			
8b:Importance-Not important	0			
8b:Importance-A little important	1			
8b:Importance-Important	22			
8b:Importance-Very important	38			
8b:Importance-Of utmost importance	20			
8b:Importance-Not applicable	0			
8b:Importance-Missing	2			
9a:Nurses interested-Not at all	0			
9a:Nurses interested-To a small extent	0			
9a:Nurses interested-To a moderate extent	4			
9a:Nurses interested-To a large extent	29			
9a:Nurses interested-To a very large extent	49			
9a:Nurses interested-Not applicable	0			
9a:Nurses interested-Missing	1			
9b:Importance-Not important	0			
9b:Importance-A little important	2			
9b:Importance-Important	27			
9b:Importance-Very important	34			
9b:Importance-Of utmost importance	18			
9b:Importance-Not applicable	0			
9b:Importance-Missing	2			
10a:Nurses interaction-Not at all	0			
10a:Nurses interaction-To a small extent	1			
10a:Nurses interaction-To a moderate extent	6			
10a:Nurses interaction-To a large extent	26			
10a:Nurses interaction-To a very large extent	49			
10a:Nurses interaction-Not applicable	0			
10a:Nurses interaction-Missing	1			
10a:Importance-Not important	0			
10a:Importance-A little important	3			
10b:Importance-Important	27			
10b:Importance-Very important	34			
10b:Importance-Of utmost importance	17			
10b:Importance-Not applicable	0			
10b:Importance-Missing	2			
11a:Nurses equipment good order-Not at all	0			
11a:Nurses equipment good order-To a small extent	0			
11a:Nurses equipment good order-To moderate extent	2			
11a:Nurses equipment good order-To a large extent	27			
11a:Nurse equipment good order-To verylarge extent	51			



11a:Nurses equipment good order-Not applicable	1			
11a:Nurses equipment good order-Missing	2			
11b:Importance-Not important	1			
11b:Importance-A little important	2			
11b:Importance-Important	21			
11b:Importance-Very important	41			
11b:Importance-Of utmost importance	17			
11b:Importance-Not applicable	0			
11b:Importance-Missing	1			
12a:Satisfaction-Not at all	0			
12a:Satisfaction-To a small extent	0			
12a:Satisfaction-To a moderate extent	0			
12a:Satisfaction-To a large extent	14			
12a:Satisfaction-To a very large extent	67			
12a:Satisfaction-Not applicable	0			
12a:Satisfaction-Missing	2			
12a:Importance-Not important	0			
12a:Importance-A little important	0			
12b:Importance-Important	18			
12b:Importance-Very important	42			
12b:Importance-Of utmost importance	22			
12b:Importance-Not applicable	0			
12b:Importance-Missing	1			
13a:Care benefit at home-Not at all	0			
13a:Care benefit at home-To a small extent	0			
13a:Care benefit at home-To moderate extent	0			
13a:Care benefit at home-To a large extent	18			
13a:Care benefit at home-To very large extent	63			
13a:Care benefit at home-Not applicable	0			
13a:Care benefit at home-Missing	2			
13b:Importance-Not important	0			
13b:Importance-A little important	1			
13b:Importance-Important	19			
13b:Importance-Very important	41			
13b:Importance-Of utmost importance	21			
13b:Importance-Not applicable	0			
13b:Importance-Missing	1			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Participant-reported Severity of Symptoms as Assessed by Monroe Dunaway Anderson Symptom Inventory (MDASI) Questionnaire

End point title	Participant-reported Severity of Symptoms as Assessed by Monroe Dunaway Anderson Symptom Inventory (MDASI)
-----------------	--

## End point description:

MDASI questionnaire is used to rate the severity of 13 core items (pain, fatigue, nausea, vomiting, disturbed sleep, distress, shortness of breath, memory difficulties, lack of appetite, drowsiness, dry mouth, sadness, numbness or tingling). Participants were asked to rate the severity of each symptom "at its worst" using 0–10 numerical rating scales with 0 = "not present" and 10 = "as bad as you can imagine." Total score was summed and ranged from 0 to 130, with lower scores indicating better outcome. ITT population. Here, N=participants who were evaluable for this endpoint and "n" included participants who were evaluable for the specified category.

End point type	Secondary
----------------	-----------

## End point timeframe:

Prior (0 hours) to Cycles 7, 10, 13, 16 (Each cycle=21 days)

End point values	Trastuzumab			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Units on a scale				
arithmetic mean (standard deviation)				
Pain- IV (Hospital) - Cycle 7 (n=101)	1.79 (± 2.51)			
Fatigue- IV (Hospital) - Cycle 7 (n=101)	3.76 (± 2.69)			
Nausea- IV (Hospital) - Cycle 7 (n=99)	0.82 (± 1.96)			
Disturbed Sleep- IV (Hospital) - Cycle 7 (n=101)	3.01 (± 2.89)			
Distressed- IV (Hospital) - Cycle 7 (n=101)	1.99 (± 2.27)			
Breath shortness- IV (Hospital) - Cycle 7 (n=101)	1.59 (± 2.13)			
Remembering things-IV (Hospital) - Cycle 7 (n=100)	1.97 (± 2.32)			
Lack of appetite-IV (Hospital) - Cycle 7 (n=101)	0.85 (± 1.8)			
Drowsy- IV (Hospital) - Cycle 7 (n=101)	2.25 (± 2.54)			
Dry mouth- IV (Hospital) - Cycle 7 (n=101)	1.89 (± 2.51)			
Feeling sad- IV (Hospital) - Cycle 7 (n=100)	1.9 (± 2.26)			
Vomiting- IV (Hospital) - Cycle 7 (n=101)	0.34 (± 1.31)			
Numbness- IV (Hospital) - Cycle 7 (n=101)	3.01 (± 3.2)			
Pain- SC (Hospital) - Cycle 10 (n=88)	1.81 (± 2.14)			
Fatigue- SC (Hospital) - Cycle 10 (n=89)	3.35 (± 2.45)			
Nausea- SC (Hospital) - Cycle 10 (n=90)	0.61 (± 1.41)			
Disturbed Sleep- SC (Hospital) - Cycle 10 (n=90)	2.7 (± 2.86)			
Distressed- SC (Hospital) - Cycle 10 (n=89)	2.1 (± 2.57)			
Breath shortness- SC (Hospital) - Cycle 10 (n=90)	1.29 (± 1.88)			
Remembering thing- SC (Hospital) - Cycle 10 (n=90)	2.01 (± 2.21)			
Lack of appetite- SC (Hospital) - Cycle 10 (n=90)	0.81 (± 1.67)			

Drowsy- SC (Hospital) - Cycle 10 (n=90)	2.32 (± 2.52)			
Dry mouth- SC (Hospital) - Cycle 10 (n=90)	1.42 (± 2.06)			
Feeling sad- SC (Hospital) - Cycle 10 (n=90)	1.87 (± 2.38)			
Vomiting- SC (Hospital) - Cycle 10 (n=89)	0.26 (± 0.81)			
Numbness- SC (Hospital) - Cycle 10 (n=90)	2.73 (± 2.76)			
Pain- SC (Home) - Cycle 13 (n=83)	1.54 (± 2.33)			
Fatigue- SC (Home) - Cycle 13 (n=86)	3.42 (± 2.27)			
Nausea- SC (Home) - Cycle 13 (n=86)	0.45 (± 1.25)			
Disturbed Sleep- SC (Home) - Cycle 13 (n=86)	2.63 (± 2.5)			
Distressed- SC (Home) - Cycle 13 (n=86)	1.81 (± 2.27)			
Breath shortness- SC (Home) - Cycle 13 (n=86)	1.28 (± 2.06)			
Remembering things- SC (Home) - Cycle 13 (n=86)	1.95 (± 2.07)			
Lack of appetite- SC (Home) - Cycle 13 (n=86)	0.43 (± 1.29)			
Drowsy- SC (Home) - Cycle 13 (n=86)	1.87 (± 2.26)			
Dry mouth- SC (Home) - Cycle 13 (n=86)	1.57 (± 2.3)			
Feeling sad- SC (Home) - Cycle 13 (n=86)	1.8 (± 2.32)			
Vomiting- SC (Home) - Cycle 13 (n=86)	0.22 (± 1.16)			
Numbness- SC (Home) - Cycle 13 (n=86)	2.51 (± 2.64)			
Pain- SC (Home) - Cycle 16 (n=83)	1.49 (± 2.06)			
Fatigue- SC (Home) - Cycle 16 (n=84)	2.79 (± 2.05)			
Nausea- SC (Home) - Cycle 16 (n=83)	0.57 (± 1.35)			
Disturbed Sleep- SC (Home) - Cycle 16 (n=83)	2.11 (± 2.28)			
Distressed- SC (Home) - Cycle 16 (n=84)	2.01 (± 2.33)			
Breath shortness- SC (Home) - Cycle 16 (n=84)	1.38 (± 2.05)			
Remembering things- SC (Home) - Cycle 16 (n=84)	2.14 (± 2.12)			
Lack of appetite- SC (Home) - Cycle 16 (n=84)	0.71 (± 1.63)			
Drowsy- SC (Home) - Cycle 16 (n=84)	1.74 (± 2.01)			
Dry mouth- SC (Home) - Cycle 16 (n=84)	1.39 (± 1.93)			
Feeling sad- SC (Home) - Cycle 16 (n=84)	1.98 (± 2.24)			
Vomiting- SC (Home) - Cycle 16 (n=83)	0.14 (± 0.61)			
Numbness- SC (Home) - Cycle 16 (n=84)	2 (± 2.29)			

## Statistical analyses

**Secondary: Participant-reported Interference of Symptoms With Life as Assessed by MDASI Questionnaire**

End point title	Participant-reported Interference of Symptoms With Life as Assessed by MDASI Questionnaire
-----------------	--

## End point description:

MDASI questionnaire is used to rate the interference of symptoms. The measure includes 6 symptom interference items which ask how much all symptoms, interfere with domains (general activity, mood, work, relations with others, walking, and enjoyment of life). Each items were rated on a 0-10 scale (0 = "did not interfere"; 10 = "interfered completely"). Lower scores indicating better outcome. Total score was summed and ranged from 0 to 50, with lower scores indicating better outcome. ITT population. Here, N=participants who were evaluable for this endpoint and "n" included participants who were evaluable for the specified category.

End point type	Secondary
----------------	-----------

## End point timeframe:

Prior (0 hours) to Cycles 7, 10, 13, 16 (Each cycle=21 days)

End point values	Trastuzumab			
Subject group type	Reporting group			
Number of subjects analysed	101			
Units: Units on a scale				
arithmetic mean (standard deviation)				
General activity- IV (Hospital) - Cycle 7 (n=101)	2.77 (± 2.73)			
Mood- IV (Hospital) - Cycle 7 (n=101)	2.11 (± 2.13)			
Work- IV (Hospital) - Cycle 7 (n=101)	3.22 (± 2.86)			
Relations- IV (Hospital) - Cycle 7 (n=101)	1.54 (± 2.13)			
Walking- IV (Hospital) - Cycle 7 (n=99)	3.34 (± 3.06)			
Enjoyment of life- IV (Hospital) - Cycle 7 (n=101)	2.51 (± 2.55)			
General activity- SC (Hospital) - Cycle 10 (n=90)	2.24 (± 2.35)			
Mood- SC (Hospital) - Cycle 10 (n=89)	1.92 (± 2.28)			
Work- SC (Hospital) - Cycle 10 (n=90)	2.63 (± 2.71)			
Relations- SC (Hospital) - Cycle 10 (n=90)	1.48 (± 2.3)			
Walking- SC (Hospital) - Cycle 10 (n=89)	2.38 (± 2.69)			
Enjoyment of life- SC (Hospital) - Cycle 10 (n=90)	2.21 (± 2.67)			
General activity- SC (Home) - Cycle 13 (n=86)	2.27 (± 2.48)			
Mood- SC (Home) - Cycle 13 (n=86)	1.81 (± 2.28)			
Work- SC (Home) - Cycle 13 (n=86)	2.35 (± 2.26)			
Relations- SC (Home) - Cycle 13 (n=86)	1.13 (± 1.93)			
Walking- SC (Home) - Cycle 13 (n=85)	2.13 (± 2.79)			
Enjoyment of life- SC (Home) - Cycle 13 (n=86)	2.06 (± 2.66)			
General activity- SC (Home) - Cycle 16 (n=82)	1.84 (± 2.12)			
Mood- SC (Home) - Cycle 16 (n=82)	1.76 (± 2.13)			

Work- SC (Home) - Cycle 16 (n=83)	2 ( $\pm$ 2.21)			
Relations- SC (Home) - Cycle 16 (n=82)	1.02 ( $\pm$ 1.85)			
Walking- SC (Home) - Cycle 16 (n=83)	1.67 ( $\pm$ 2.41)			
Enjoyment of life- SC (Home) - Cycle 16 (n=83)	1.9 ( $\pm$ 2.37)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Modalities Assessed Using Patient Experience Questionnaires (PEX) - Part 1:In-Hospital

End point title	Number of Participants With Modalities Assessed Using Patient Experience Questionnaires (PEX) - Part 1:In-Hospital
-----------------	--

End point description:

PEX-Part 1 questionnaire contains 25 items to assess participant's experience on use of trastuzumab at hospital.1.Place of treatment?2.Was it same place as for chemotherapy?3.How long did it take to travel there?4.How easy was travel?5.Company required for travelling?6.Was travelling cost a problem?7.Considering all these,was travelling for treatment overall a problem?8.How helpful were nursing/medical staff?9.How pleasant was place of study?10.How was IV treatment given?11.If Venous Access Device(VAD),what was it?12.Did hospital staff have difficulty inserting cannula?13.Time for cannulation?14.How painful was IV?15.How much time to access port/line usually take?16.How painful was it?17.Time for IV sessions?18.Anxiety level while IV treatment?19.How would you describe IV sessions?20.Did hospital staff have difficulty giving SC?21.Time for SC?22.How painful was SC?23.Time for SC sessions?24.Anxiety level while SC treatment?25.How would you describe SC sessions? ITT

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (0 hours) to Cycle 12 (Cycle length=21 days)

End point values	Trastuzumab			
Subject group type	Reporting group			
Number of subjects analysed	102			
Units: Participants				
number (not applicable)				
Place of study treatment: hospital chemo dept	87			
Place of study treatment: other chemo clinic	0			
Place of study treatment: Doctor's office	0			
Place of study treatment: other	0			
Place of study treatment: missing	15			
Same place as for your chemotherapy: yes	87			
Same place as for your chemotherapy: no	0			
Same place as for your chemotherapy: missing	15			
Travel time: <1 hour	70			
Travel time: 1-2 hours	12			
Travel time: >2 hours	5			
Travel time: missing	15			

Travelling easy: not at all	9			
Travelling easy: fairly	44			
Travelling easy: very	34			
Travelling easy: missing	15			
Company required for travelling: always	32			
Company required for travelling: sometimes	19			
Company required for travelling: never	36			
Company required for travelling: missing	15			
Travelling cost, a problem: not at all	60			
Travelling cost, a problem: fairly	23			
Travelling cost, a problem: very	4			
Travelling cost, a problem: missing	15			
Travelling overall, a problem: yes	18			
Travelling overall, a problem: no	69			
Travelling overall, a problem: missing	15			
Nursing and medical staff helpful: not at all	0			
Nursing and medical staff helpful: fairly	15			
Nursing and medical staff helpful: very	72			
Nursing and medical staff helpful: missing	15			
Pleasant place of treatment: not at all	3			
Pleasant place of treatment: fairly	39			
Pleasant place of treatment: very	44			
Pleasant place of treatment: missing	16			
IV administration method: cannula/needle	34			
IV administration method: Venous Access Device(VAD)	47			
IV administration method: both	6			
IV administration method: missing	15			
VAD: Hickman	0			
VAD: peripherally inserted central catheters	5			
VAD: port-a-cath	47			
VAD: other	9			
VAD: missing	41			
Difficulty inserting the cannula: very often	5			
Difficulty inserting the cannula: sometimes	15			
Difficulty inserting the cannula: never	22			
Difficulty inserting the cannula: missing	60			
Time for insertion of the cannula: <5 minutes	30			
Time for insertion of the cannula: 6-10 minutes	7			
Time for insertion of the cannula: 11-15 minutes	1			
Time for insertion of the cannula: 16-20 minutes	0			
Time for insertion of the cannula: >20 minutes	2			
Time for insertion of the cannula: missing	62			

Cannulation painful: not at all	20			
Cannulation painful: fairly	18			
Cannulation painful: very	4			
Cannulation painful: missing	60			
Time for connection to the access port: <5 minutes	39			
Time for connection to access port: 6-10 minutes	8			
Time for connection to access port: 11-15 minutes	1			
Time for connection to access port: 16-20 minutes	1			
Time for connection to access port: >20 minutes	0			
Time for connection to access port: missing	53			
Connection painful: not at all	36			
Connection painful: fairly	14			
Connection painful: very	0			
Connection painful: missing	52			
Time for IV session: <2 hours	21			
Time for IV session: 2-3 hours	25			
Time for IV session: 3-4 hours	26			
Time for IV session: >4 hours	13			
Time for IV session: missing	17			
Anxiety during IV treatment: not at all	64			
Anxiety during IV treatment: fairly	20			
Anxiety during IV treatment: very	2			
Anxiety during IV treatment: missing	16			
General IV session: very unpleasant	2			
General IV session: fairly unpleasant	15			
General IV session: acceptable	68			
General IV session: missing	17			
Difficulty in SC injection: very often	0			
Difficulty in SC injection: sometimes	4			
Difficulty in SC injection: never	82			
Difficulty in SC injection: missing	16			
Time for SC injection: <5 minutes	56			
Time for SC injection: 6-10 minutes	26			
Time for SC injection: 11-15 minutes	1			
Time for SC injection: 16-20 minutes	0			
Time for SC injection: >20 minutes	3			
Time for SC injection: missing	16			
SC injection painful: not at all	53			
SC injection painful: fairly	33			
SC injection painful: very	1			
SC injection painful: missing	15			
Time for SC session: <2 hours	46			
Time for SC session: 2-3 hours	24			
Time for SC session: 3-4 hours	9			
Time for SC session: >4 hours	7			
Time for SC session: missing	16			
Anxiety during SC treatment: not at all	63			
Anxiety during SC treatment: fairly	21			

Anxiety during SC treatment: very	3			
Anxiety during SC treatment: missing	15			
General SC session: very unpleasant	0			
General SC session: fairly unpleasant	7			
General SC session: acceptable	79			
General SC session: missing	16			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Modalities Assessed Using PEX - Part 2: At Home

End point title	Number of Participants With Modalities Assessed Using PEX - Part 2: At Home
-----------------	---

End point description:

PEX - Part 2 questionnaire contains 6 items to assess the participant's experience on the use of trastuzumab SC vials at home. Participants answered the following questions: 1. Did the nursing staff ever have any difficulty giving the trastuzumab injection SC? 2. How many minutes did the injection (it) usually take? 3. How painful was this usually? 4. How long did the SC sessions usually last from arrival until departure of the nurse? 5. How anxious did having the SC treatment make you feel? 6. In general how would you describe these SC treatment sessions at home? ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

1 months after end of treatment (up to 10 months)

End point values	Trastuzumab			
Subject group type	Reporting group			
Number of subjects analysed	102			
Units: Participants				
number (not applicable)				
Difficulty in SC administration: very often	0			
Difficulty in SC administration: sometimes	5			
Difficulty in SC administration: never	77			
Difficulty in SC administration: missing	20			
SC administration time: <5 minutes	65			
SC administration time: 6-10 minutes	17			
SC administration time: 11-15 minutes	0			
SC administration time: 16-20 minutes	0			
SC administration time: >20 minutes	0			
SC administration time: missing	20			
SC administration Painful: not at all	61			
SC administration Painful: fairly	20			
SC administration Painful: very	0			
SC administration Painful: missing	21			
Time for SC session: <2 hours	82			
Time for SC session: 2-3 hours	0			



Time for SC session: 3-4 hours	0			
Time for SC session: >4 hours	0			
Time for SC session: missing	20			
Anxiety during SC treatment: not at all	71			
Anxiety during SC treatment: fairly	11			
Anxiety during SC treatment: very	0			
Anxiety during SC treatment: missing	20			
General SC session: very unpleasant	3			
General SC session: fairly unpleasant	0			
General SC session: acceptable	79			
General SC session: missing	20			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Health Care Professional With Modalities Assessed Using Health Care Professional Questionnaire (HCPEX-1)

End point title	Number of Health Care Professional With Modalities Assessed Using Health Care Professional Questionnaire (HCPEX-1)
-----------------	--

End point description:

HCPEX-1 questionnaire is used to assess health care professional's (HCP) overall satisfaction and perceived time savings with trastuzumab SC vial in the hospital. The HCPEX-1 questionnaire (19 questions) was completed by the HCP administering the trastuzumab IV and SC in the hospital after at least 3 participants had completed the in-hospital part of the study. ITT population. Here, N=number of HCP participated in the study.

End point type	Secondary
----------------	-----------

End point timeframe:

Prior (0 hours) to Cycle 12 (Cycle length=21 days)

End point values	Trastuzumab			
Subject group type	Reporting group			
Number of subjects analysed	21			
Units: Health care professional				
number (not applicable)				
Specialty: Oncologist	0			
Specialty: Gynecologist	0			
Specialty: Oncologist/ Specialist Chemo Nurse	19			
Specialty: Other	2			
Specialty: Missing	0			
Personal administration of SC: always	6			
Personal administration of SC: sometimes	15			
Personal administration of SC: never	0			
Personal administration of SC: missing	0			
Time required for SC preparation: <5 minutes	7			

Time required for SC preparation: 6-10 minutes	2			
Time required for SC preparation: 11-15 minutes	1			
Time required for SC preparation: 16-20 minutes	1			
Time required for SC preparation: >20 minutes	1			
Time required for SC preparation: not sure	9			
Time required for SC preparation: missing	0			
Time required for SC administration: <3 minutes	1			
Time required for SC administration: <5 minutes	16			
Time required for SC administration: 6-15 minutes	3			
Time required for SC administration: 16-30 minutes	1			
Time required for SC administration: 31-60 minutes	0			
Time required for SC administration: 61-90 minutes	0			
Time required for SC administration: >90 minutes	0			
Time required for SC administration: not sure	0			
Time required for SC administration: missing	0			
Time for SC session: <2 hours	14			
Time for SC session: 2-3 hours	7			
Time for SC session: 3-4 hours	0			
Time for SC session: >4 hours	0			
Time for SC session: missing	0			
Reliability of SC hand held syringe: not at all	0			
Reliability of SC hand held syringe: fairly	10			
Reliability of SC hand held syringe: very	11			
Reliability of SC hand held syringe: missing	0			
Easy to administer SC hand held syringe: not at all	0			
Easy to administer SC hand held syringe: fairly	13			
Easy to administer SC hand held syringe: very	8			
Easy to administer SC hand held syringe: missing	0			
convenient method for IV treatment- cannula	7			
convenient method for IV treatment- VAD	14			
convenient method for IV treatment- not sure	0			
convenient method for IV treatment- missing	0			
Personally administer IV: always	4			
Personally administer IV: sometimes	15			

Personally administer IV: never	2			
Personally administer IV: missing	0			
Personally Cannulate: always	5			
Personally Cannulate: sometimes	10			
Personally Cannulate: never	5			
Personally Cannulate: missing	1			
Time for IV preparation: <5 minutes	1			
Time for IV preparation: 6-10 minutes	2			
Time for IV preparation: 11-15 minutes	2			
Time for IV preparation: 16-20 minutes	1			
Time for IV preparation: >20 minutes	5			
Time for IV preparation: not sure	10			
Time for IV preparation: missing	0			
Time for cannulation: <5 minutes	8			
Time for cannulation: 6-10 minutes	4			
Time for cannulation: 11-15 minutes	1			
Time for cannulation: 16-20 minutes	0			
Time for cannulation: >20 minutes	2			
Time for cannulation: not sure	5			
Time for cannulation: missing	1			
Time for connection: <3 minutes	1			
Time for connection: <5 minutes	3			
Time for connection: 6-15 minutes	0			
Time for connection: 16-30 minutes	2			
Time for connection: 31-60 minutes	8			
Time for connection: 61-90 minutes	5			
Time for connection: >90 minutes	1			
Time for connection: not sure	1			
Time for connection: missing	0			
Time for IV session: <2 hours	5			
Time for IV session: 2-3 hours	11			
Time for IV session: 3-4 hours	4			
Time for IV session: >4 hours	1			
Time for IV session: missing	0			
Anxiety during IV treatment: not at all	14			
Anxiety during IV treatment: fairly	6			
Anxiety during IV treatment: very	1			
Anxiety during IV treatment: missing	0			
Reliability of IV treatment: not at all	0			
Reliability of IV treatment: fairly	8			
Reliability of IV treatment: very	13			
Reliability of IV treatment: missing	0			
IV administration easy: not at all	0			
IV administration easy: fairly	12			
IV administration easy: very	9			
IV administration easy: missing	0			
Quickest administration: IV	0			
Quickest administration: SC (handheld syringe)	21			
Quickest administration: no difference	0			
Quickest administration: missing	0			
Require less resource: IV	0			

Require less resource: SC (handheld syringe)	21			
Require less resource: no difference	0			
Require less resource: missing	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Disease-Free Survival (DFS) as Assessed by Routine Clinical, Radiological and Laboratory Criteria

End point title	Disease-Free Survival (DFS) as Assessed by Routine Clinical, Radiological and Laboratory Criteria
-----------------	---

End point description:

DFS was defined as time from first study drug administration (i.e. Day 1 of Cycle 7) to local, regional or distant recurrence, contralateral breast cancer or death from any cause (whichever occurred first). Diagnosis of breast cancer relapse was made based on routine clinical, radiological and laboratory criteria. Acceptable methods of confirmation of recurrence included radiology, computerized tomography (CT) scan, brain scan, ultrasound, or cytology, as per local practice. In case of uncertainty, disease relapse was to be confirmed by histological or cytological examination of a suspicious lesion, if possible. ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of treatment up to 45 months

<b>End point values</b>	Trastuzumab			
Subject group type	Reporting group			
Number of subjects analysed	0 <sup>[2]</sup>			
Units: Months				
median (confidence interval 95%)	( to )			

Notes:

[2] - Median and 95% CI could not be calculated due to low number of events.

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 45 months

Adverse event reporting additional description:

Safety population

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.0
--------------------	------

### Reporting groups

Reporting group title	Trastuzumab
-----------------------	-------------

Reporting group description:

Participants received trastuzumab IV infusion at initial loading dose of 8 mg/kg/BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (Cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).

Serious adverse events	Trastuzumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 101 (7.92%)		
number of deaths (all causes)	2		
number of deaths resulting from adverse events	0		
Investigations			
Ejection fraction decreased			
subjects affected / exposed	5 / 101 (4.95%)		
occurrences causally related to treatment / all	5 / 5		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Lymphoedema			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Infections and infestations			
Infected lymphocele			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Trastuzumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	44 / 101 (43.56%)		
General disorders and administration site conditions			
Injection site erythema			
subjects affected / exposed	14 / 101 (13.86%)		
occurrences (all)	44		
Injection site swelling			
subjects affected / exposed	14 / 101 (13.86%)		
occurrences (all)	31		
Fatigue			
subjects affected / exposed	34 / 101 (33.66%)		
occurrences (all)	41		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
07 February 2014	The Investigator's Brochure for Herceptin (trastuzumab /RO452317) had been recently updated to version 14, October 2013 with recommendation to submit the mentioned update as substantial amendment to the local Health Authority (HA)/Ethics Committee (EC). The update is related to the change from the 6 to 7 months period for contraception/avoidance of pregnancy following the last study drug administration date.
20 October 2015	Following changes were made to the protocol: Administrative corrections to the table of schedule of assessments. Update of the description of the internal data monitoring committee. Deletion of the contact details of the medical monitor in the section emergency contacts.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported